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ABSTRACT 
 
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that may play an 
important role in the evolution of cancers, due to their effects on cancer cell metabolism. Statins 
effect several potential pathways, including: cell proliferation, angiogenesis, apoptosis and 
metastasis. The number of trials assessing the putative clinical benefits of statins in cancer is 
increasing. Currently, there are several trials listed on the global trial identifier website 
clinicaltrials.gov. Given the compelling evidence from these trials in a variety of clinical settings, there 
have been calls for a clinical trial of statins in the adjuvant gastrointestinal cancer setting. However, 
randomized controlled trials on specific cancer types in relation to statin use, as well as studies on 
populations without a clinical indication for using statins, have elucidated some potential underlying 
biological mechanisms, and the investigation of different statins is probably warranted. It would be 
useful for these trials to incorporate the assessment of tumour biomarkers predictive of statin 
response in their design. This review summarizes the recent preclinical and clinical studies that assess 
the application of statins in the treatment of gastrointestinal cancers with particular emphasize on 
their association with cancer risk.    
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Introduction 
Gastrointestinal (GI) cancer is the third most common cause of cancer death globally, with 
more than 700,000 deaths a year[1]. Gastrointestinal cancers include: esophageal, stomach, liver, 
pancreas, and colorectal cancer (CRC)[2, 3]. Patient with late stage GI cancer have a poorer survival 
and drug efficacy[4]. Gastrointestinal cancers may be the consequence of non-regulation of many 
cellular and molecular activities such as apoptosis, cell cycle, proliferation, and DNA repair [5-7]. The 
pathways, and molecules involved in the development of cancer, require different treatments. 
Several cohort studies have demonstrated that increased cholesterol intake plays an important role 
in cancers such as colorectal cancers.[8, 9] Several studies have shown that, statins may reduce the 
incidence of several gastrointestinal cancers[10-13].  Kuoppala, J., et al. (2008) in a meta-analysis and 
systematic review on 42 trials (17 randomized controlled trials, 10 cohort studies, and 15 case-
control studies) showed that, statins protect from stomach and liver cancers[14]. Singh and Singh 
demonstrated that, statin treatment was associated with a 32% reduction in the risk of GC[15]. 
Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase[16-18]. Statins were initially discovered in the 1970s and were approved to treat of 
hypercholesterolemia[19, 20]. This enzyme plays an important role in the mevalonate pathway and 
ultimately in the synthesis of cholesterol, reducing LDL-cholesterol [21, 22], and reducing 
cardiovascular disease morbidity and mortality.  
Statins are actively transported into the cell via plasma membrane ATP-binding cassette (ABC) 
and solute carriers (SLC) superfamilies [23]. The ABC family of transporters consists of three 
members: P-glycoprotein (Pg-P/ ABCB1), breast cancer resistance protein (BCRP/ABCG2), and 
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multidrug resistance-associated proteins (MRP1/ ABCC1 and MRP2/ABCC2). A reduction in the 
activity of these proteins makes the statin more effective. [24]. The SLC superfamily is the family of 
organic anion transporting polypeptides (OATP/SLCO). Pharmacokinetics and pharmacodynamics of 
statins are dependent on changes in the SLC family[25]. 
As studies show, useful information may be obtained empirically or theoretically in the 
developments of drugs. On the other hand, discovering or designing drugs in health is very 
important, so many techniques are used. In this regard, the Nuclear Magnetic Resonance (NMR) has 
the unique ability to combine atomic spatial resolution with high temporal resolution in several 
widely different frequency regimes. This technique also gives us a lot of useful information about 
drugs, through 3D (three-dimensional) membrane protein structures[26-31]. As a hightropout 
technique, NMR provides a lot of information on chemistry, medicine or geophysics[32]. Thus this 
technique is the most beneficial techniques for drug discovery[27, 29]. To develop various prediction 
methods for proteome/genome analysis[33-39], the Chou’s 5-step rules [40] should be followed. To 
timely get 3D structures of the target proteins the structural bioinformatics is needed[41-45]. 
Statins also play an important role in controlling Rho-A activity [46] in some disease such as 
cancers and HIV [47, 48] Kwak, B., et al. in 2000 demonstrated that, statins act as immunomodulatory 
via controlling MHC-II and T- lymphocyte activity[49]. Blocking MHC-II Statins decrease MMP-9 
(matrix metalloproteinase 9)[50], downregulate B cell and T cell chemokine receptors, and improve 
Th1/Th2 cytokine balance. As well as, statins inhibit IFNβ-1b[51].  
On the other side, one of the goals of the pharmaceutical industry is the development of 
multi-purpose drugs that require a multi-label technique and approach[52-59]. Lee et al. showed that 
5 
 
simvastatin may improve the anti-angiogenic effects of bevacizumab in CRC trough repressing 
angiopoietin2, BiP, and Hsp90α in cancer cells[60]. As because of drug-drug interactions (DDI) 
between statins and antibiotics, doctors can avoid ordering clarithromycin and erythromycin for 
older patients who take cholesterol-lowering statin drugs[61]. To treat cancers and other diseases, 
knowledge of various posttranslational modification (PTM) positions in proteins, DNA, and RNA play 
a major role[62-64]. And the PseAAC [65, 66] and PseKNC[67-69] approaches are very useful in this. 
Hence, a lot of studies developed to demonstrate the statin efficacy on disease such as 
cancers. In this regard, Klawitter, J., et al. in 2010, to demonstrate several target of antitumor activity 
of lovastatin, used a combination of proteomics and metabonomics[70]. Several studies have shown 
that, statins may also prevent cancers (Table 1) and reduce cancer mortality[71-73]. Brown and 
Goldstein showed that, mevalonate and cholesterol synthesis have an effect on cell growth[74]. 
Reducing mevalonate can effect cellular signaling, and cell cycle progression. [75] Statins also induce 
apoptosis via cell cycle arrest in G1 phase. This could have beneficial effects by inhibiting tumor 
development [76] in cancers including colorectal cancer(CRC). [77, 78]  
CRC is a common GI cancer that is associated with a high mortality. Notarnicola et al. 
demonstrated that, the effects of HMG-CoA reductase in colorectal cancer cells is greater in relation 
to natural mucosal cells. It proposed that the cholesterol synthesis plays an important role in the 
development and evolution of CRC and may be potentially involved in the development of 
malignancy. [79] A meta-analysis of 32 trials by Bardou, et al. demonstrated that, statin treatment 
was associated with a reduction jn CRC invasion and metastasis. Statins also appear to increase 
tumor sensitivity in combination with anti-cancer agents.[80] Gray et al. have shown that, the 
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likelihood of the survival in patients with CRC treated with statins is also increased.[81] There is a 
significant negative association between the use of long-term statin therapy and the risk of colorectal 
cancer[80, 82]. 
Virchow made a connection between cancer and inflammation[83]. The anti-inflammatory 
activity of statins has been reported in several studies [84]. They regulate important proinflammatory 
cytokine and molecule such as TNF, IL-6, IL-1[85, 86], CRP[87], CD 40 and CD40 L[88]. The activity of 
immune cells can be controlled by statins. MHC-II (major histocompatibility complexes class II) is 
controlled by statin via IFN-γ (interferon-γ) inhibition[89]. They down-regulate the expression of 
MHC-II that leads to a reduction in the differentiation and activation of Th1 and 2 (T helper 1)[89].      
To alleviate the biased consequence caused by the imbalanced benchmark datasets in 
biomedical or biological systems[90-92], the IHTS (inserting hypothetical training samples) 
treatment[93, 94] is a very effective approach. To follow the role of statins within GI cancers trials, 
we summarize this review, which carries 29 clinical trials that include esophageal, stomach, 
pancreatic, gastric, liver, and CRC cancers. 
The statin mechanisms involved in reducing CRC risk : 
HMG-CoA reductase (HMGR) plays an important role in the mevalonate synthesis pathway. 
This enzyme produces mevalonic acid, a cholesterol precursor from HMG-CoA.[95] This process 
occurs predominantly in the liver, but occurs in all cells.[96] Statins may either be active 
(Atorvastatin, Cerivastatin, Fluvastatin and pravastatin), or pro-drugs (Lovastatin and Simvastatin). 
[97] Lovastatin, Simvastatin, Atorvastatin and Cerivastatin are metabolized by cytochrome P450 (CYP 
3A4) and Fluvastatin via the CYP 2C9 pathway.[98, 99] Given the efficacy and safety of statins, they 
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are widely used to treat patients with hypercholesterolemia. Statins also have other pleiotropic 
effects, stimulating the development of new blood vessels[100], osteogenic stimulation[101], 
reducing serum C-reactive protein levels (CRP) [102]. 
Statin and cancers:  
It has been reported that the statins probably act as a tumor suppressor in several different 
solid tumors, that include: esophageal[103], gastric[104], pancreatic[11], and rectal carcinoma[105]. 
In addition, statins may have beneficial effects on CRC in both prevention and treatment via several 
mechanisms[80]. Statins down-regulate the anti-apoptotic (BCl2 or cIAP1) and increase of 
proapoptotic (BMP) proteins that lead to apoptosis in CRC[106-109]. In additional statins cause the 
upregulation of other proapoptotic proteins such as bax and Bim[78, 110, 111]. It causes the release 
of cytochrome c from the mitochondria[112]. This process leads to enhanced caspase 9, as well as 
caspase 1,3, 7, and 8 directly[113, 114]. 
 Statins may reduce cell proliferation[115], by G0/G10 cell cycle arrest[116] in CRC but also in 
breast cancer[117]. It may inhibit vascular endothelial growth factor (VEGF) as a major regulator of 
angiogenesis. Simvastatin inhibits VEGF via NF-KB, which is an angiogenic mediator. Thus statins 
inhibit proangiogenic pathways[107]. Studies have shown that the reduction in metastatic is rare by 
statins[118, 119]. however, Kusama et al. in a study on human pancreatic cancer cell invasion in vitro 
and experimental liver metastasis in vivo showed that, HMGR inhibitors may be potentially useful for 
clinical applications because of their anti-metastatic effects[120]. 
Statins can have beneficial effects on cancers via their epigenetic effects. Zeste homolog 2 
(EZH2) acts as a silencer in epigenetic. statin increased p27KIP1 via EZH2, and finally statins inhibit 
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tumor progression[121]. Kodach et al. (2007) demonstrated that,SMAD4 plays an important role in 
the statin effect[122] . 
Statins play an inhibitory role in cell cycle progression (Table 1). Tumor proliferation has been 
blocked by statins through cell cycle arrest via P21Cip1/WAF1 and P27Kip1 expression. These molecules as 
cyclin dependent kinase (CDK) inhibitor, have been enhanced by statin and modulate cell cycle. That 
is why the cell cycle stopped at G1 stage[123, 124]. And also because, cyclin and CDKs play key a role 
in the cell cycle, statins via inhibition these causes arrest cell cycle[125]. Statins trough down-
regulation of cyclin D1 (CycD), cyclin E (CycE), cyclin dependent kinase (CDK) 4 expression, and CDK2  
prevent cancer cell growth.  Inhibition of the phosphorylation of Retinoblastoma protein (Rb) is 
another putative mechanism, that allows statins to blocked the cell cycle. This occurs via stabilization 
of the transcriptionally passive complex E2F-Rb[126]. Farnesylated and geranylgeranylated proteins 
are reduced by HMGR inhibitors such as statins. These proteins make K-Ras and RHO/RAC 
respectively that are localized on plasma membrane[127]. This delocalization finally inactivated Rho-
kinase pathway and is due to enhance cell migration, metastatic[128]. Tumors increase the 
anthracyclines sensitivity by inhibiting K-Ras farnesylation inhibition[129]. In addition, Akt and 
MAPK/ERK activity are inhibited by statins directly[130]. In the end, statins inhibit adapter protein 1 
(AP1) and NF-κB transcription factors[131]. 
Statins and CRC 
Simvastatin induces apoptosis in models of colorectal cancer (HCT116) by stimulating the p38MAPK-
p53-survivin cascade[132]. In xenograft models, simvastatin arrested angiogenesis[107]. One of the 
major causes of cancers are gene mutations. These may have a role in determining treatment. A K-
Ras mutation is found in nearly 30% of patients with solid tumors. Statins can lower the expression of 
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the mutated KRAS protein by inhibition of protein prenylation. Therefore, this event make the 
Epidermal Growth Factor Receptor (EGFR) antibody susceptible to KRAS mutation in the CRC.[133] 
Simvastatin, when used with cetuximab, increases the anti-cancer function in KRAS mutation in 
human CRC cell line.[134] However in the NCT01190462 trials, 80mg simvastatin per day did not 
affect cetuximab susceptibility on KRAS gene mutation in the CRC patients. (NCT01190462) In the 
other study, a combination of 80mg simvastatin plus cetuximab and irinotecan was performed in the 
KRAS mutation of CRC by Lee, J., et al. This study showed that, compared to wild-type CRCs, no 
change in resistance to cetuximab was observed in KRAS mutation, and thus simvastatin may 
overcome cetuximab resistance(NCT01281761).[135] Some other clinical trials as combination anti-
cancer therapy with simvastatin are registered. Panitumumab is another human monoclonal 
antibody directed against EGFR and was combined with simvastatin in the NCT01110785 trial. 
XELIRI (irinotecan plus capecitabine) and FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) are other 
drugs that combined with simvastatin(NCT01238094). In this phase III randomised, placebo-
controlled study, toxicity of the XELIRI or FOLFIRI didn’t rise by simvastatin in low dose. 40 mg of 
simvastatin in this trial has no beneficial anti-cancer effects when combined with cytotoxic 
chemotherapy[136]. Another combination therapy of simvastatin with capecitabine, oxaliplatin, and 
bevacizumab for stage IV CRC is ongoing in phase II(NCT02026583). 
 FOLFIRI is combined with atorvastatin in step 1 in advanced colon or rectum adenocarcinoma in the 
NCT01605344 trial (Table 1). 
Phase 3 trial of rosuvastatin for stage 1 and 2 colon cancer was undertaken in the NCT01011478 trial. 
Chemo radiation therapy (CRT) as the standard treatment of locally advanced rectal cancer plus 
rosuvastatin used in NCT02569645 trial. This phase 2 trial is for both prognostic and predictive of 
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response and toxicity to treatment that recognized genetic, serological, and pathological biomarkers 
(Table 1). 
Statins and liver cancer 
In cirrhosis, simvastatin has been tested in phase II trials to study Alpha-fetoprotein-L 3% (AFP-L3%) 
changes. (NCT02968810) Atorvastatin is used in the NCT03024684 trial to prevent the recurrence of 
hepatocellular carcinoma (HCC) after curative treatment, as well as pravastatin on HCC recurrence in 
early stage HCC patients at the trial of NCT03219372.  The survivability, tumor responses, and PFS are 
the goals of the NCT03275376 study. In this study atorvastatin was used in HCC patients receiving 
sorafenib. Pravastatin is also included in NCT01903694 trial with sorafenib to measure their effect on 
overall survival in patients with HCC. The other study of pravastatin with sorafenib in patients with 
HCC is NCT01357486. 
 
Statins in Gastric cancer 
Because of progression-free survival (PFS) in advanced gastric adenocarcinoma was not improved by 
treatment with simvastatin plus capecitabine–cisplatin (XP) compare with XP alone, thus the 
NCT01099085 trial doesn’t recommended low dose of simvastatin (40 mg) to chemotherapy in 
untargeted population with advanced gastric cancer (AGC)[137]. Statins have beneficial effects on 
inflammation trough in a variety of ways, including reducing the synthesis of inflammatory 
cytokines[137]. The purpose of NCT01813994 trial was to evaluate the role of statin in gastric cancer 
by using inflammatory stomach variables on patients at high risk of gastric cancers. 
Statins and pancreatic cancer 
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Simvastatin has side effect on pancreatic cancer by sonic hedgehog pathway deactivation. These 
beneficial effects can prevent live ability of tumor, tumor growth and metastasis. All this makes the 
gemcitabine more effective in pancreatic cancer [43]. The purpose of the NCT02201381 trial was to 
find the effect of metabolic therapy such as metformin, atorvastatin, doxycycline, and mebendazole 
in cancer patients. 
Statins on esophageal Cancer 
Pravastatin has been tested in NCT01038154 as a strong statin in advanced stage gastroesophageal 
cancer. The goal of the 4th phase of this study was to investigate the effect of pravastatin on survival 
and recurrence of advanced gastroesophageal cancer (NCT01038154). 
Conclusion  
There is growing body of data showing the therapeutic potential value of statins in the treatment of 
GI and their roles in carcinogenesis, due to their effect on the cancer cell metabolism. They can 
modulate several cellular and molecular processes including cell proliferation, metastasis, 
angiogenesis, and apoptosis, via inhibiting the downstream production of isoprenoids, matrix 
metalloproteinases, Ras/Rho, RAF/MEK-ERK pathways as well as cyclin-dependent kinases. It has also 
reported to be involved in the degradation of stroma components [21, 129, 138, 139]. Moreover, 
several reports showed their values to induce cancer cell death and the therapeutic potential of 
these agents as an adjuvant in combination therapies. Furthermore, several studies have illustrated 
their activities in prostate, breast, colorectal and pancreas cancers, as well as chemopreventive 
activity against hematopoietic malignancies and lung cancer patients with chronic obstructive 
pulmonary disease [140, 141]. Furthermore parallel targeting of different dysregulated pathways in 
GI, such as PI3K/Akt/mTOR, Wnt/b-catenin, TGF-b, RAS/MAP/ERK pathways are required to 
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overcome cell resistance or suppress the possible feedback loop between these signaling pathways  
[142]. However we can not exclude the possible side effect of different cytotoxic agents which can 
thereby enhanced toxicity. These provide a proofs of concept of the need for assessing natural 
compound, such as curcumin or crocin as well [143][107-108].  
Authors Insight On the Topic 
The future research should work on the (1) optimization and evaluation of statins alone or their 
combination with other dysregulated pathways, (2) identification of GI patient who could most 
benefit from therapy, (3) recognition of markers which can be used for monitoring treatment 
response; and to (4) explore molecular mechanism behind the antitumor and chemopreventive 
mechanisms of these agents in the treatment of gastrointestinal cancers. 
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119. NÜBEL, T., et al., Lovastatin inhibits Rho-regulated expression of E-selectin by TNFα and attenuates 
tumor cell adhesion. The FASEB journal, 2004. 18(1): p. 140-142. 
120. Kusama, T., et al., 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human 
pancreatic cancer cell invasion and metastasis. Gastroenterology, 2002. 122(2): p. 308-317. 
121. Ishikawa, S., et al., Statins inhibit tumor progression via an enhancer of zeste homolog 2‐mediated 
epigenetic alteration in colorectal cancer. International journal of cancer, 2014. 135(11): p. 2528-2536. 
122. Kodach, L.L., et al., The effect of statins in colorectal cancer is mediated through the bone 
morphogenetic protein pathway. Gastroenterology, 2007. 133(4): p. 1272-1281. 
123. DeClue, J.E., et al., Inhibition of cell growth by lovastatin is independent of ras function. Cancer 
Research, 1991. 51(2): p. 712-717. 
124. Hirai, A., et al., Geranylgeranylated rho small GTPase (s) are essential for the degradation of p27Kip1 
and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. Journal of 
Biological Chemistry, 1997. 272(1): p. 13-16. 
125. Rao, S., et al., Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of 
CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene, 1998. 17(18): p. 2393. 
126. Zetterberg, A., O. Larsson, and K.G. Wiman, What is the restriction point? Current opinion in cell 
biology, 1995. 7(6): p. 835-842. 
127. Sebti, S.M. and C.J. Der, Searching for the elusive targets of farnesyltransferase inhibitors. Nature 
Reviews Cancer, 2003. 3(12): p. 945. 
19 
 
128. Ridley, A.J., Rho family proteins: coordinating cell responses. Trends in cell biology, 2001. 11(12): p. 
471-477. 
129. Roudier, E., O. Mistafa, and U. Stenius, Statins induce mammalian target of rapamycin (mTOR)-
mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Molecular 
cancer therapeutics, 2006. 5(11): p. 2706-2715. 
130. Nishida, S., et al., Mevastatin induces apoptosis in HL60 cells dependently on decrease in 
phosphorylated ERK. Molecular and cellular biochemistry, 2005. 269(1): p. 109-114. 
131. Li, J., et al., Atorvastatin Decreases C‐Reactive Protein‐Induced Inflammatory Response in Pulmonary 
Artery Smooth Muscle Cells by Inhibiting Nuclear Factor‐κB Pathway. Cardiovascular therapeutics, 
2010. 28(1): p. 8-14. 
132. Chang, H.-L., et al., Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-
p53-survivin signaling cascade. Biochimica et Biophysica Acta (BBA)-General Subjects, 2013. 1830(8): 
p. 4053-4064. 
133. Krens, L.L., et al., Therapeutic modulation of k-ras signaling in colorectal cancer. Drug discovery today, 
2010. 15(13-14): p. 502-516. 
134. Lee, J., et al., Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS 
mutations. JNCI: Journal of the National Cancer Institute, 2011. 103(8): p. 674-688. 
135. Lee, J., et al., Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and 
predictive value of the RAS signature for treatment response to cetuximab. Investigational new drugs, 
2014. 32(3): p. 535-541. 
136. Lim, S., et al., A randomised, double-blind, placebo-controlled multi-centre phase III trial of 
XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. British journal of cancer, 
2015. 113(10): p. 1421. 
137. Dulak, J. and A. Józkowicz, Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-
cancer therapy. Current cancer drug targets, 2005. 5(8): p. 579-594. 
138. Tsubaki, M., et al., Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the 
expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma. Cytokine, 2011. 
54(1): p. 100-107. 
139. Ortego, M., et al., Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth 
muscle cells and mononuclear cells. Atherosclerosis, 1999. 147(2): p. 253-261. 
140. Neil, A., et al., Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with 
heterozygous familial hypercholesterolaemia: a prospective registry study. European heart journal, 
2008. 29(21): p. 2625-2633. 
141. Laufs, U., et al., 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth 
muscle proliferation by preventing rho GTPase-induced down-regulation of p27 Kip1. Journal of 
Biological Chemistry, 1999. 274(31): p. 21926-21931. 
142. Bahrami, A., et al., The therapeutic potential of targeting the BRAF mutation in patients with colorectal 
cancer. Journal of cellular physiology, 2018. 233(3): p. 2162-2169. 
143. Parizadeh, S.M., et al., Epigenetic drug therapy in the treatment of colorectal cancer. Current 
pharmaceutical design, 2018. 
144. Shyamsundar, M., et al., Effect of simvastatin on physiological and biological outcomes in patients 
undergoing esophagectomy: a randomized placebo-controlled trial. Annals of surgery, 2014. 259(1): p. 
26-31. 
 
 
 
20 
 
 
 
 
 
 
Table 1: The impact of statin therapy in patients with gastrointestinal cancer 
Study Intervention/ treatment Phase Start date End date Disease type Key Word 
CRC 
Simvastatin in Colorectal Surgery Simvastatin Placebo 3 October 14, 
2009 
2-Dec-13 Colorectal Surgery 
(StatCol) 
NCT00994903 
Rosuvastatin in Treating Patients With 
Stage I or Stage II Colon Cancer That was 
Removed by Surgery 
Rosuvastatin Placebo 3 11-Nov-09 April 11, 
2016 
Stage I or Stage II 
Colon Cancer 
NCT01011478 
Crossover Evaluation of Effect of 
Atorvastatin on PK of Irinotecan in CRC 
Patients Receiving FOLFIRI 
Atorvastatin FOLFIRI 1 24-May-12 27-Feb-14 Advanced 
adenocarcinoma of 
the colon or rectum 
NCT01605344 
Atorvastatin, Oligofructose-Enriched 
Inulin, or Sulindac in Preventing Cancer in 
Patients at Increased Risk of Developing 
Colorectal Neoplasia 
Atorvastatin Oligofructose-
enriched 
inulin/ 
Sulindac / 
placeb / 
Other: 
laboratory 
biomarker 
analysis 
2 12-Jun-06 15-Feb-17 Colorectal NCT00335504 
Cetuximab and Simvastatin in Treating 
Patients With Advanced or Metastatic 
Colorectal Cancer 
Simvastatin Biological: 
cetuximab / 
Other: 
laboratory 
biomarker 
analysis 
2 August 27, 
2010 
12-Aug-13 Advanced or 
Metastatic 
Colorectal Cancer 
NCT01190462 
Simvastatin and Panitumumab in Treating 
Patients With Advanced or Metastatic 
Colorectal Cancer 
Simvastatin Panitumumab 2 27-Apr-10 17-Sep-13 Advanced or 
Metastatic 
Colorectal Cancer 
NCT01110785 
Simvastatin + Cetuximab/Irinotecan in K-
ras Mutant Colorectal Cancer 
Simvastatin Cetuximab/Iri
notecan 
2 24-Jan-11 14-Jun-13 Metastatic 
colorectal 
NCT01281761 
Trial of XELIRI/FOLFIRI + Simvastatin 
Followed by Simvastatin Maintenance in 
Metastatic Colorectal Cancer 
Simvastatin XELIRI/FOLFIRI 3 10-Nov-10 14-Jun-13 Metastatic 
Colorectal Cancer 
NCT01238094 
Phase II Study of Simvastatin Plus 
Irinotecan, Fluorouracil, and Leucovorin 
(FOLFIRI) for Metastatic CRC 
Simvastatin FOLFIRI 2 12-Apr-06 2-Feb-12 Metastatic CRC NCT00313859 
Rosuvastatin in the Treatment of 
Rectal Cancer 
Rosuvastatin  2 7-Oct-15 June 14, 
2018 
Rectal Cancer NCT02569645 
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A Single Arm, Phase II Study of 
Simvastatin Plus XELOX and Bevacizumab 
as First-line Chemotherapy in Metastatic 
Colorectal CancerPatients 
Simvastatin capecitabine, 
oxaliplatin, 
and 
bevacizumab 
2 3-Jan-14 17-Jan-18 Metastatic 
Colorectal Cancer 
Patients 
NCT02026583 
Capecitabine Plus Simvastatin in Locally 
Advanced Rectal CancerPatients 
Simvastatin capecitabine 
with radiation 
2 12-Jun-14 17-Jan-18 Adenocarcinoma of 
Rectum 
NCT02161822 
 
Liver 
Simvastatin in Preventing Liver Cancer in 
Patients With Liver Cirrhosis 
Simvastatin Placebo / 
Questionnaire 
Administratio
n / Other: 
Laboratory 
Biomarker 
Analysis 
2 21-Nov-16 17-Jul-18 Cirrhosis  
NCT02968810 
Effects of Statin on Hepatocellular 
Carcinoma Recurrence 
After LiverTransplantation 
Statins   April 6, 2018 April 6, 2018 Hepatocellular 
Carcinoma 
NCT03490461 
The Combination Effect of Statin Plus 
Metformin on Relapse-free 
Statins Metformin 2 30-Jun-16 19-Apr-17 Hepatocellular 
Carcinoma 
NCT02819869 
Statin for Preventing Hepatocellular 
Carcinoma Recurrence After Curative 
Treatment (SHOT) 
Atorvastatin Placebo Oral 
Tablet 
4 19-Jan-17 25-Jan-17 HepatoCellular 
Carcinoma 
NCT03024684 
Statin Combination Therapy in Patients 
Receiving Sorafenib for Advanced 
Hepatocellular Carcinoma 
Atorvastatin Placebo Oral 
Tablet 
2 7-Sep-17 11-Jan-18 Advanced 
Hepatocellular 
Carcinoma 
NCT03275376 
Pravastatin Intervention to Delay 
Hepatocellular Carcinoma Recurrence 
Pravastatin Pill Placebo Oral 
Tablet 
2 17-Jul-17 July 18, 2018 Hepatocellular 
Carcinoma 
Liver Cirrhoses 
NCT03219372 
Randomized Trial Sorafenib-Pravastatin 
Versus Sorafenib Alone for the Palliative 
Treatment of Child-Pugh A 
Hepatocellular Carcinoma 
Pravastatin Sorafenib + 
Pravastatin 
3 19-Jul-13 May 13, 
2014 
Child-Pugh A 
Hepatocellular 
Carcinoma 
NCT01903694 
Sorafenib Tosylate With or Without 
Pravastatin in Treating Patients With 
Liver Cancer and Cirrhosis 
Pravastatin 
sodium 
Sorafenib 
Tosylate 
3 25-Feb-10 27-May-16 Liver Cancer and 
Cirrhosis 
NCT01075555 
Palliative Treatment of Hepatocellular 
Carcinoma in Patient With CHILD B 
Cirrhosis (PRODIGE 21) 
Pravastatin sorafenib / 
Sorafenib + 
Pravastatin/ 
Other: 
patients 
receiving best 
supportive 
care 
2 20-May-11 12-Apr-17 Hepatocellular 
carcinoma|CHILD B 
NCT01357486 
Efficacy and Safety Study of Sorafenib 
Plus Pravastatin to Treat Advanced 
Hepatocarcinoma (ESTAHEP-2010) 
Pravastatin  2 17-Aug-11 Jun-17 Advanced 
hepatocarcinoma 
NCT01418729 
Gastric cancer 
Trial of XP (Capecitabine/CDDP) 
Simvastatin in Advanced Gastric Cancer 
Patients 
Simvastatin 
Placebo( 
capecitabine–
cisplatin (XP)) 
3 6-Apr-10 17-Feb-17 Gastric cancer NCT01099085 
A Phase I Study of High Dose Simvastatin 
in Patients With Gastrointestinal Tract 
Cancer Who Failed to Standard 
Chemotherapy 
Simvastatin   1 
January 4, 
2018 
December 
2019 
Stomach Cancer NCT03086291 
Role of Statin on the Gastric 
Inflammation in Patients at High Risk of 
Gastric Cancer 
Simvastatin Placebo 
Not 
Applic
able 
19-Mar-13 28-May-14 
Early 
Gastric Cancer or 
Gastric Adenoma 
NCT01813994 
22 
 
Pancreatic Cancer 
Trial of Simvastatin and Gemcitabine in 
Pancreatic Cancer Patients 
Simvastatin 
Gemcitabine+
simvastatin / 
Gemcitabine+
Placebo 
2 23-Jul-09 17-Feb-17 Pancreatic Cancer NCT00944463 
Study of the Safety, Tolerability and 
Efficacy of Metabolic Combination 
Treatments on Cancer (METRICS) 
Atorvastatin 
Metformin 
Doxycycline 
Mebendazole 
3 28-Jul-14 3-Aug-18 
CancerOverall 
Survival 
NCT02201381 
Esophageal Cancer / Stomach Cancer 
Study to Evaluate the Efficacy of 
Pravastatin on Survival and Recurrence 
of Advanced 
Gastroesophageal Cancer (AGIM-1) Pravastatin 
  4 23-Dec-09 27-Jun-11 
Esophageal Cancer 
/ Stomach Cancer 
NCT01038154 
Effect of Simvastatin on Physiological 
and Biological Outcomes in Patients 
Undergoing Esophagectomy Simvastatin 
Placebo   2007 2010 Esophagectomy 
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